296 related articles for article (PubMed ID: 17896893)
1. Prevalence and risk factors for clinically significant drug interactions with antiretroviral therapy.
Miller CD; El-Kholi R; Faragon JJ; Lodise TP
Pharmacotherapy; 2007 Oct; 27(10):1379-86. PubMed ID: 17896893
[TBL] [Abstract][Full Text] [Related]
2. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.
Patel N; Abdelsayed S; Veve M; Miller CD
Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025
[TBL] [Abstract][Full Text] [Related]
3. Identification of potential clinically significant drug interactions in HIV-infected patients: a comprehensive therapeutic approach.
Iniesta-Navalón C; Franco-Miguel JJ; Gascón-Cánovas JJ; Rentero-Redondo L
HIV Med; 2015 May; 16(5):273-9. PubMed ID: 25523089
[TBL] [Abstract][Full Text] [Related]
4. Clinically significant drug interactions in younger and older human immunodeficiency virus-positive patients receiving antiretroviral therapy.
Yiu P; Nguyen NN; Holodniy M
Pharmacotherapy; 2011 May; 31(5):480-9. PubMed ID: 21923429
[TBL] [Abstract][Full Text] [Related]
5. [Predictive factors of clinically significant drug-drug interactions among regimens based on protease inhibitors, non-nucleoside reverse transcriptase inhibitors and raltegravir].
Cervero M; Torres R; Jusdado JJ; Pastor S; Agud JL
Med Clin (Barc); 2016 Apr; 146(8):339-45. PubMed ID: 26971988
[TBL] [Abstract][Full Text] [Related]
6. Short communication metabolic and mitochondrial effects of switching antiretroviral-experienced patients to enfuvirtide, tenofovir and saquinavir/ritonavir.
Miró O; Garrabou G; López S; Deig E; Vidal I; Infante AB; Cardellach F; Casademont J; Pedrol E
Antivir Ther; 2006; 11(5):625-30. PubMed ID: 16964831
[TBL] [Abstract][Full Text] [Related]
7. Recognition of possible risk factors for clinically significant drug-drug interactions among Indian people living with HIV receiving highly active antiretroviral therapy and concomitant medications.
Priyanka PSSL; Varma DM; Immadisetti K; Rajesh R; Vidyasagar S; Guddattu V
Int J Risk Saf Med; 2017; 29(1-2):25-55. PubMed ID: 28885219
[TBL] [Abstract][Full Text] [Related]
8. Enfuvirtide in HIV-1-infected individuals changing therapy to a nucleoside reverse transcriptase inhibitor sparing regimen: the ALLIANCE Study.
Dwyer DE; Workman C; Hales G; Amin J; Cooper D; Miller J;
Antivir Ther; 2006; 11(4):409-19. PubMed ID: 16856614
[TBL] [Abstract][Full Text] [Related]
9. Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis.
Sungkanuparph S; Overton ET; Seyfried W; Groger RK; Fraser VJ; Powderly WG
Clin Infect Dis; 2005 Nov; 41(9):1326-32. PubMed ID: 16206110
[TBL] [Abstract][Full Text] [Related]
10. Acute pancreatitis associated with different combination therapies in patients infected with human immunodeficiency virus.
Guo JJ; Jang R; Louder A; Cluxton RJ
Pharmacotherapy; 2005 Aug; 25(8):1044-54. PubMed ID: 16207094
[TBL] [Abstract][Full Text] [Related]
11. Raltegravir: new Drug. Alternative to enfuvirtide/darunavir in multidrug-resistant HIV.
Prescrire Int; 2008 Aug; 17(96):135-7. PubMed ID: 19480091
[TBL] [Abstract][Full Text] [Related]
12. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.
Lalezari JP; Henry K; O'Hearn M; Montaner JS; Piliero PJ; Trottier B; Walmsley S; Cohen C; Kuritzkes DR; Eron JJ; Chung J; DeMasi R; Donatacci L; Drobnes C; Delehanty J; Salgo M;
N Engl J Med; 2003 May; 348(22):2175-85. PubMed ID: 12637625
[TBL] [Abstract][Full Text] [Related]
13. Consensus recommendation from a group of German experts for the use of enfuvirtide in heavily pretreated HIV patients.
Salzberger B; Däumer M; Gute P; Jaeger H; Knechten H; van Lunzen J; Mauss S; Mayr C; Moll A; Plettenberg A; Rockstroh J; Staszewski S; Stellbrink HJ; Stoll M; Sturmer M
Eur J Med Res; 2007 Mar; 12(3):93-102. PubMed ID: 17507306
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcomes of HIV-infected patients with Kaposi's sarcoma receiving nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy in Uganda.
Asiimwe F; Moore D; Were W; Nakityo R; Campbell J; Barasa A; Mermin J; Kaharuza F
HIV Med; 2012 Mar; 13(3):166-71. PubMed ID: 22112164
[TBL] [Abstract][Full Text] [Related]
15. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
[TBL] [Abstract][Full Text] [Related]
16. Long-term survival of HIV-infected patients treated with highly active antiretroviral therapy in Serbia and Montenegro.
Jevtović DO; Salemović D; Ranin J; Pesić I; Zerjav S; Djurković-Djaković O
HIV Med; 2007 Mar; 8(2):75-9. PubMed ID: 17352762
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia.
Lazzarin A; Clotet B; Cooper D; Reynes J; Arastéh K; Nelson M; Katlama C; Stellbrink HJ; Delfraissy JF; Lange J; Huson L; DeMasi R; Wat C; Delehanty J; Drobnes C; Salgo M;
N Engl J Med; 2003 May; 348(22):2186-95. PubMed ID: 12773645
[TBL] [Abstract][Full Text] [Related]
18. Amdoxovir versus placebo with enfuvirtide plus optimized background therapy for HIV-1-infected subjects failing current therapy (AACTG A5118).
Gripshover BM; Ribaudo H; Santana J; Gerber JG; Campbell TB; Hogg E; Jarocki B; Hammer SM; Kuritzkes DR;
Antivir Ther; 2006; 11(5):619-23. PubMed ID: 16964830
[TBL] [Abstract][Full Text] [Related]
19. Switching from a toxicity-causing antiretroviral to enfuvirtide in patients with HIV: the SWITCH TOX study.
Streinu-Cercel A; de Gorgolas M; Müller M; Portilla J; Rugina S; Böcher W; Staszewski S; Pulik P; Rowell L; Salgo M; Stoll M
HIV Clin Trials; 2008; 9(6):375-86. PubMed ID: 19203903
[TBL] [Abstract][Full Text] [Related]
20. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
